Open AccessHealth-Related Quality of Life as a Prognostic Measure of Clinical Outcomes in Renal Cell Carcinoma: A Review of the CheckMate 025 Trial
Author(s) -
Marc-Oliver Grimm,
Viktor Grünwald
Publication year - 2017
Publication title -
oncology and therapy
Language(s) - English
Resource type - Journals
eISSN - 2366-1070
pISSN - 2366-1089
DOI - 10.1007/s40487-017-0042-6
Subject(s) - medicine , nivolumab , quality of life (healthcare) , everolimus , renal cell carcinoma , clinical trial , randomized controlled trial , oncology , health related quality of life , intensive care medicine , cancer , immunotherapy , nursing , disease
The phase III, randomized, open-label CheckMate 025 study showed an overall survival benefit in patients with advanced renal cell carcinoma treated with nivolumab versus everolimus. Here, we review the health-related quality of life (HRQoL) results of this trial, in which nivolumab was associated with significant improvements in HRQoL, with more patients having a clinically meaningful HRQoL improvement and a shorter time to onset of improvement compared with everolimus. Further exploratory analysis suggests a positive correlation between baseline HRQoL scores and overall survival. These results support the use of HRQoL as a valuable measure of patient perspective that could translate into better clinical outcomes and should be taken into account during treatment selection.